Nectin-4: a Novel Therapeutic Target for Skin Cancers
Sign Up to like & getrecommendations! Published in 2022 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-022-00940-w
Abstract: Nectin-4 is a tumor-associated antigen that is highly expressed on various cancer cells, and it has been further proposed to have roles in tumor development and propagation ranging from cellular proliferation to motility and invasion.… read more here.
Keywords: nectin; enfortumab vedotin; novel therapeutic; target ... See more keywords
Upcoming market catalysts in Q1 2020
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Drug Discovery"
DOI: 10.1038/d41573-019-00211-8
Abstract: 2020 include US approval decisions for enfortumab vedotin for urothelial cancer, AR101 for peanut allergy and ozanimod for multiple sclerosis. Astellas and Seattle Genetics are developing enfortumab vedotin for the treatment of urothelial cancer. This… read more here.
Keywords: market; enfortumab vedotin; approval; urothelial cancer ... See more keywords
The biology and rationale of targeting nectin-4 in urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Urology"
DOI: 10.1038/s41585-020-00394-5
Abstract: Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the most common type of bladder cancer and accounts for 90% of bladder cancer cases in the USA and Europe. Novel approaches… read more here.
Keywords: advanced metastatic; carcinoma; enfortumab vedotin; urothelial carcinoma ... See more keywords
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2069563
Abstract: ABSTRACT Introduction Metastatic urothelial carcinoma is an aggressive malignancy with a poor prognosis. Research in recent years has led to the approval of new treatments that offer improved survival for patients. Enfortumab vedotin-ejfv is a… read more here.
Keywords: vedotin ejfv; enfortumab vedotin; urothelial carcinoma;
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-1764
Abstract: Abstract Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior… read more here.
Keywords: nectin expression; enfortumab vedotin; membranous nectin; expression ... See more keywords
Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.463
Abstract: 463Background: Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting Nectin-4 (encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic urothelial cancer. Fac... read more here.
Keywords: heterogeneity nectin; nectin expression; enfortumab vedotin; urothelial cancer ... See more keywords
Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.472
Abstract: 472Background: Enfortumab Vedotin (EV), an antibody-drug conjugate that targets nectin-4, is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therap... read more here.
Keywords: urothelial carcinoma; metastatic urothelial; enfortumab vedotin; carcinoma muc ... See more keywords
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Management and Research"
DOI: 10.2147/cmar.s224223
Abstract: Abstract Enfortumab vedotin (EV) is an antibody–drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was… read more here.
Keywords: treatment; cancer; urothelial cancer; metastatic urothelial ... See more keywords
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Sign Up to like & getrecommendations! Published in 2021 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s240854
Abstract: Abstract Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug… read more here.
Keywords: urothelial carcinoma; enfortumab vedotin; vedotin treatment; carcinoma ... See more keywords
Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.801199
Abstract: Introduction Enfortumab vedotin (EV) has been demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile. Emerging case reports have raised awareness of cutaneous toxicities, which… read more here.
Keywords: ror; enfortumab vedotin; cutaneous toxicities; food drug ... See more keywords